Gamco Investors INC. ET AL Has $25.38 Million Stock Position in Henry Schein, Inc. $HSIC

Gamco Investors INC. ET AL grew its position in Henry Schein, Inc. (NASDAQ:HSIC) by 5.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 382,452 shares of the company’s stock after acquiring an additional 20,257 shares during the quarter. Gamco Investors INC. ET AL owned 0.32% of Henry Schein worth $25,383,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Artisan Partners Limited Partnership increased its position in shares of Henry Schein by 5.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock valued at $453,509,000 after purchasing an additional 370,837 shares during the period. Dimensional Fund Advisors LP lifted its position in Henry Schein by 6.5% in the third quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock worth $172,304,000 after purchasing an additional 159,087 shares during the period. Ameriprise Financial Inc. boosted its stake in Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after buying an additional 2,199,695 shares in the last quarter. Schroder Investment Management Group increased its holdings in Henry Schein by 149.3% in the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after buying an additional 936,471 shares during the period. Finally, Snyder Capital Management L P increased its holdings in Henry Schein by 18.6% in the 3rd quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company’s stock valued at $88,562,000 after buying an additional 209,123 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Down 3.2%

Shares of Henry Schein stock opened at $77.60 on Friday. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $89.29. The stock has a market capitalization of $8.90 billion, a P/E ratio of 23.73, a price-to-earnings-growth ratio of 2.37 and a beta of 0.88. The company has a 50-day simple moving average of $78.20 and a 200 day simple moving average of $72.57. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HSIC. Barclays started coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Wall Street Zen raised shares of Henry Schein from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company lifted their price objective on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $85.58.

Insider Activity

In related news, Director Philip A. Laskawy sold 2,844 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director directly owned 21,961 shares in the company, valued at $1,764,785.96. This represents a 11.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stanley M. Bergman sold 43,812 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $81.31, for a total value of $3,562,353.72. Following the sale, the chief executive officer directly owned 383,803 shares of the company’s stock, valued at $31,207,021.93. This represents a 10.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 101,712 shares of company stock worth $8,251,789. Insiders own 1.08% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.